Lambda Life, Bratislava, Slovak Republic.
Physiol Res. 2023 Oct 27;72(S3):S209-S224. doi: 10.33549/physiolres.935155.
Our knowledge of tumor-infiltrating lymphocytes (TILs) is dramatically expanding. These cells have proven prognostic and therapeutic value for many cancer outcomes and potential to treat also disseminated breast, colorectal, or lung cancer. However, the therapeutical outcome of TILs is negatively affected by tumor mutational burden and neoantigens. On the other hand, it can be improved in combination with checkpoint blockade therapy. This knowledge and rapid detection techniques alongside gene editing allow us to classify and modify T cells in many ways. Hence, to tailor them precisely to the patient´s needs as to program T cell receptors to recognize specific tumor-associated neoantigens and to insert them into lymphocytes or to select tumor neoantigen-specific T cells, for the development of vaccines that recognize tumor-specific antigens in tumors or metastases. Further studies and clinical trials in the field are needed for an even better-detailed understanding of TILs interactions and aiming in the fight against multiple cancers.
我们对肿瘤浸润淋巴细胞（TILs）的了解正在迅速扩展。这些细胞已被证明对许多癌症的预后和治疗具有价值，并有可能治疗转移性乳腺癌、结直肠癌或肺癌。然而，TILs 的治疗效果受到肿瘤突变负担和新抗原的负面影响。另一方面，它可以与检查点阻断疗法联合使用来改善。这些知识和快速检测技术以及基因编辑使我们能够以多种方式对 T 细胞进行分类和修饰。因此，可以根据患者的需求精确地对 T 细胞受体进行编程，以识别特定的肿瘤相关新抗原，并将其插入淋巴细胞中，或者选择肿瘤新抗原特异性 T 细胞，用于开发能够识别肿瘤或转移灶中肿瘤特异性抗原的疫苗。为了更深入地了解 TILs 的相互作用，并针对多种癌症进行靶向治疗，还需要进一步的研究和临床试验。
